Cutaneous Side Effects of Antiosteoporosis Treatments
暂无分享,去创建一个
J. Reginster | R. Rizzoli | J. Kaufman | P. Cacoub | P. Musette | M. Brandi
[1] J. Treat. Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2010, Pediatric annals.
[2] E. Autret‐Leca,et al. Strontium ranelate‐induced DRESS syndrome: first two case reports , 2009, Allergy.
[3] A. Boada,et al. Generalized cutaneous drug eruption due to strontium ranelate , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] W. Pichler,et al. Mechanisms of drug-induced allergy. , 2009, Mayo Clinic proceedings.
[5] J. Eisman,et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.
[6] Sherri-Ann M. Burnett-Bowie. Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture? , 2008, Nature Clinical Practice Endocrinology &Metabolism.
[7] Liam Smeeth,et al. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. , 2008, British journal of clinical pharmacology.
[8] K. Aouam,et al. Cutaneous vasculitis induced by risedronate , 2008, Allergy.
[9] I. Pernicova,et al. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert , 2008, Osteoporosis International.
[10] W. Aberer,et al. Clinical manifestations and mechanisms of skin reactions after systemic drug administration , 2008 .
[11] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[12] M. McMenamin,et al. Interstitial granulomatous reaction to strontium ranelate. , 2008, Archives of dermatology.
[13] P. Frosch,et al. Adverse cutaneous drug reaction to alendronate , 2007, Contact dermatitis.
[14] T. Shiohara,et al. Drug-Induced Hypersensitivity Syndrome and Viral Reactivation , 2007 .
[15] J. Roujeau,et al. Clinic and Pathogenesis of Severe Bullous Skin Reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis , 2007 .
[16] H. Milionis,et al. Fever with rash following zolendronic acid administration. , 2006, Clinical and experimental rheumatology.
[17] P. Miller,et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .
[18] P. Demoly,et al. Epidemiology of hypersensitivity drug reactions. , 2005, Current opinion in allergy and clinical immunology.
[19] S. Shakir,et al. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England , 2005, Osteoporosis International.
[20] S. Shakir,et al. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study , 2005, Osteoporosis International.
[21] J. Roujeau. Clinical heterogeneity of drug hypersensitivity. , 2005, Toxicology.
[22] Yuan-Tsong Chen,et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. Wolf,et al. Life-threatening acute adverse cutaneous drug reactions. , 2005, Clinics in dermatology.
[24] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[25] W. Morison. Clinical practice. Photosensitivity. , 2004, The New England journal of medicine.
[26] C. Cockerell,et al. Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. , 2003, Journal of the American Academy of Dermatology.
[27] S. Shakir,et al. Pharmacovigilance study of alendronate in England , 2003, Osteoporosis International.
[28] A. Kawada,et al. Photoallergic contact dermatitis due to diclofenac , 2003, Contact dermatitis.
[29] A. Lazarov,et al. Alendronate-induced lichen planus. , 2002, The Israel Medical Association journal : IMAJ.
[30] M. Bigby. Rates of cutaneous reactions to drugs. , 2001, Archives of dermatology.
[31] I. Edwards,et al. Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.
[32] I. Ilias,et al. Urticaria after administration of alendronate. , 2000, Acta dermato-venereologica.
[33] J. Eisman,et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.
[34] J. Tschopp,et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.
[35] D. Zehnder,et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20‐year survey , 1997, Allergy.
[36] J. Roujeau,et al. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). , 1996, Seminars in cutaneous medicine and surgery.
[37] B. Tank,et al. Cutaneous drug reactions. , 1996, Indian journal of dermatology, venereology and leprology.
[38] R. Wallace,et al. Costs and health effects of osteoporotic fractures. , 1994, Bone.
[39] C. Cooper,et al. Population-based study of survival after osteoporotic fractures. , 1993, American journal of epidemiology.
[40] O. Faye,et al. Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg) , 2012, Drugs.
[41] V. Paradis,et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. , 2009, Archives of dermatology.
[42] H. Y. Lee,et al. Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis , 2008, Osteoporosis International.
[43] L. Naldi,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.
[44] J. Roujeau,et al. Drug-Induced Skin, Nail and Hair Disorders , 2007, Drug safety.
[45] M. Mockenhaupt. Epidemiology and Causes of Severe Cutaneous Adverse Reactions to Drugs , 2007 .
[46] T. Shiohara,et al. Drug-induced Hypersensitivity Syndrome(DIHS): A Reaction Induced by a Complex Interplay among Herpesviruses and Antiviral and Antidrug Immune Responses. , 2006, Allergology international : official journal of the Japanese Society of Allergology.
[47] O. Faye,et al. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. , 2005, Drugs.
[48] J. Roujeau,et al. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. , 2002, Dermatology online journal.
[49] J. Bentin,et al. Costs Induced by Hip Fractures: A Prospective Controlled Study in Belgium , 2000, Osteoporosis International.